1.33
+0(+0.00%)
Currency In USD
| Previous Close | 1.33 |
| Open | 1.37 |
| Day High | 1.39 |
| Day Low | 1.32 |
| 52-Week High | 1.96 |
| 52-Week Low | 0.52 |
| Volume | 3.72M |
| Average Volume | 4.49M |
| Market Cap | 435.34M |
| PE | -6.05 |
| EPS | -0.22 |
| Moving Average 50 Days | 1.44 |
| Moving Average 200 Days | 1.21 |
| Change | 0 |
If you invested $1000 in Ocugen, Inc. (OCGN) 10 years ago, it would be worth $8.83 as of February 07, 2026 at a share price of $1.33. Whereas If you bought $1000 worth of Ocugen, Inc. (OCGN) shares 5 years ago, it would be worth $84.12 as of February 07, 2026 at a share price of $1.33.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Ocugen, Inc. Announces Closing of $22.5 Million Underwritten Registered Direct Offering of Common Stock
GlobeNewswire Inc.
Jan 23, 2026 1:00 PM GMT
MALVERN, Pa., Jan. 23, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the closing of its previously announced underwritten registered direct offering
Ocugen, Inc. Announces Pricing of $22.5 Million Offering of Common Stock
GlobeNewswire Inc.
Jan 21, 2026 1:32 PM GMT
MALVERN, Pa., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the pricing of its underwritten offering of 15,000,000 shares of its common sto
Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
GlobeNewswire Inc.
Jan 15, 2026 1:15 PM GMT
Phase 2 (~50% of patients evaluated to date at 12 months) shows 46% lesion growth reduction vs. controlThere are no OCU410-related serious adverse events reported across the Phase 1 and Phase 2 clinical trials to date MALVERN, Pa., Jan. 15, 2026 (G